debt_leverage_profile
Minimal debt; SciSparc operates near cash-funded with no significant long-term debt; 20% rate rise has negligible P&L impact
Inferred
Agent_Inference
interest_rate_sensitivity
Low sensitivity; company holds cash reserves and lacks meaningful floating-rate debt; rate changes affect investment income marginally
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Israel-based clinical operations exposed to Middle East instability; API/active pharmaceutical ingredient sourcing dependent on European and Asian suppliers
Inferred
Agent_Inference
international_expansion_readiness
Limited international revenue; primary exposure is NIS/USD devaluation risk given Israel HQ; USD-denominated trials reduce FX sensitivity somewhat
Inferred
Agent_Inference
geographic_footprint
Primarily Israel and US; NIS devaluation is key sovereign currency risk; minimal exposure to EM currency volatility beyond Israel
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High dependency on single CRO partners for clinical trials; substitution feasible but costly and time-consuming; likely >30% operational input concentration
Inferred
Agent_Inference
business_model_type_primary
Clinical-stage pharma/biotech; cloud infrastructure disruption would impact administrative functions only; core R&D not cloud-critical
Inferred
Agent_Inference
business_model_type_secondary
Pre-revenue drug development; no SaaS or cloud-native revenue stream; cloud termination causes operational delay, not existential risk
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; company uses standard clinical data and ERP tools; no proprietary API lock-in identified
Inferred
Agent_Inference
howey_test_risk_index
Revenue model is grant/licensing/equity-funded R&D, not a token or investment contract; Howey Test risk is low
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Clinical trial patient data subject to GDPR (EU trials) and Israeli privacy law; CCPA exposure minimal; compliance costs manageable but real
Inferred
Agent_Inference
antitrust_exposure_flag
Negligible antitrust risk; pre-revenue micro-cap pharma with no market dominance; no horizontal or vertical concentration concerns
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Near 100% transactional/grant-based; no recurring subscription revenue; milestone and licensing payments are episodic and deal-dependent
Inferred
Agent_Inference
monetization_vector
Licensing deals, sublicensing of drug candidates, potential future royalties; no subscription or retainer revenue currently
Inferred
Agent_Inference
pricing_architecture
No commercial pricing architecture; drug pricing will be subject to payer/regulatory negotiation post-approval; pre-revenue stage limits stress-testing
Inferred
Agent_Inference
pricing_power_rating
Undetermined; pricing power contingent on orphan drug designation and market exclusivity of pipeline candidates; potentially high if approved
Inferred
Agent_Inference
target_gross_margin_bracket
Pharma licensing/royalty gross margins typically 70–90%; SciSparc's model targets this bracket upon commercialization
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider problem; IP-protected pipeline; no subscription product subject to churn; clinical milestone dependency is primary risk
Inferred
Agent_Inference
headcount_cost_structure
Headcount-linear to sublinear; small team (~20 employees); outsourced clinical ops to CROs means revenue scaling doesn't require proportional hiring
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth is capital-intensive (clinical trials) not headcount-intensive; CRO outsourcing model keeps fixed headcount low
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; SciSparc does not operate a franchise network
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC undefined pre-revenue; licensing deal economics depend on Big Pharma partner appetite; no traditional CAC metric applicable
Inferred
Agent_Inference
network_effect_present
No network effects present; pharmaceutical R&D pipeline has no user-driven network dynamics
Inferred
Agent_Inference
asset_efficiency_ratio
AI displacement risk low for core drug development; AI may accelerate trial design and data analysis, representing opportunity not threat
Inferred
Agent_Inference
recession_resistance_tier
Low recession resistance; clinical-stage biotech funding dries up in downturns; equity raises become more dilutive or unavailable
Inferred
Agent_Inference
customer_segment_primary
Pharmaceutical licensing partners and Big Pharma acquirers; highly concentrated with potential single-partner dependency per asset
Inferred
Agent_Inference
customer_segment_secondary
Government grant bodies and research institutions; secondary funding source with competitive application processes
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocated toward clinical trial milestones and pipeline advancement; no legacy infrastructure reallocation; burn-rate funded by equity issuance
Inferred
Agent_Inference
sec_cik
0001611746
High
SEC-EDGAR
ticker
SPRC
High
SEC-EDGAR